API Pomalidomide Purity Pomalidomide Powder Pomalidomide

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Still deciding? Get samples of US$ 30/kg
Request Sample
Diamond Member Since 2021

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Management System Certification
ISO 9001, ISO 14001, GMP, HACCP
  • API Pomalidomide Purity Pomalidomide Powder Pomalidomide
  • API Pomalidomide Purity Pomalidomide Powder Pomalidomide
  • API Pomalidomide Purity Pomalidomide Powder Pomalidomide
  • API Pomalidomide Purity Pomalidomide Powder Pomalidomide
  • API Pomalidomide Purity Pomalidomide Powder Pomalidomide
  • API Pomalidomide Purity Pomalidomide Powder Pomalidomide
Find Similar Products
  • Overview
  • Product Description
  • Product Details
  • Application&Function
  • Specification
Overview

Basic Info.

Model NO.
D-sung Pomalidomide
Certification
GMP, HSE, ISO 9001, USP, BP
Suitable for
Elderly, Adult
State
Powder
Purity
>99%
Product Name
Pomalidomide
Name
Pomalidomide Powder
Appearance
Yellow Powder
Color
Yellow
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Pharmaceutical
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
19171-19-8
Mf
C13h11n3o4
MW
273.24
Melting Point
318.5 - 320.5 C
Boiling Point
582.9 C
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
1000kg/Month

Product Description

API Pomalidomide Purity Pomalidomide Powder Pomalidomide
API Pomalidomide Purity Pomalidomide Powder Pomalidomide
Product Description
API Pomalidomide Purity Pomalidomide Powder PomalidomideAPI Pomalidomide Purity Pomalidomide Powder Pomalidomide
Product Details
API Pomalidomide Purity Pomalidomide Powder Pomalidomide
Product Name Pomalidomide 
Appearance Yellow Powder
CAS No. 19171-19-8
MF C13H11N3O4

Pomalidomide is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.

Application&Function
API Pomalidomide Purity Pomalidomide Powder Pomalidomide

Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Specification
API Pomalidomide Purity Pomalidomide Powder PomalidomideAPI Pomalidomide Purity Pomalidomide Powder PomalidomideAPI Pomalidomide Purity Pomalidomide Powder Pomalidomide
API Pomalidomide Purity Pomalidomide Powder PomalidomideAPI Pomalidomide Purity Pomalidomide Powder PomalidomideAPI Pomalidomide Purity Pomalidomide Powder Pomalidomide
API Pomalidomide Purity Pomalidomide Powder Pomalidomide
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier